City of Hope, Duarte, California
A STELLAR 2019 Has Positioned AGT For A SPECTACULAR 2020. I wanted to take a moment to sum up a great year of progress and success at AGT and to talk about potential milestones and significant inflection points ...
A private biotechnology company developing cures and treatments
for Infectious diseases, cancers and monogenic disorders.
AGT, has a broad, robust lentiviral delivery platform evolved over ten years of advanced development. AGT has an extensive and growing patent portfolio surrounding its lentiviral platform innovations that accelerate the development of a wide variety of drug candidates. This platform allows AGT to pursue exciting clinical “cures” in large and orphan indications and complex diseases. AGT’s proprietary platform technologies provide reusable components that allow AGT and its internationally recognized collaborators to create new therapies in a fraction of the time of traditional drug development processes and other drug companies. AGT is expecting to begin clinical trials this year for an HIV cure based on a successful pre-IND meetings with the FDA.
AGT has built a rich product pipeline of genetic therapies for patients suffering from infectious disease, monogenic disorders, and cancer, using its lentiviral vector platform and patented methods.
AGT’s patent portfolio protects its technology platform and methods. In addition to below, AGT has several patents pending and over 20 patent families represented by filings with the USPTO and international patent offices. Also, AGT has been granted FDA Orphan Drug Designation for its treatment of Phenylketonuria (PKU).
At The Harvard Club, NYC
Hosted By AGT
Zacks Small Cap Research (SCR)
AGT is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding AGT’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of AGT or its management. AGT does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Contact us for any investor relations questions and sign-up to receive AGT's latest financial news & events.
Send this to a friend